Experts in managing R&D biomed projects providing practical support and strategic guidance to scientific coordinators throughout the whole project life cycle.
📢 Breaking news for VICT3R: European Medicines Agency Qualification Opinion released for public consultation, focusing on the application of Virtual Control Groups.
SYNAPSE has been involved in this qualification process as the official applicant.
https://t.co/9bXRvd0Y0n
Today is #WorldMSDay 🧡
CLAIMS aims to revolutionise #MultipleSclerosis care by developing a data-driven tool for treatment optimisation, improving long-term patient outcomes and reducing the economic burden on individuals and society.
👉 https://t.co/AT35AYmyrQ
#MS#AI
New milestone! We're proud to announce that the recruitment target for our pilot study on digital cognitive assessments has been successfully reached.
👏A huge thank you to all partners, study teams & participants who made this milestone possible.
➡️ https://t.co/JxYo5WukHi
Our Innovative Health Initiative (IHI) funded @IHI_PROMINENT project kicks off 2026 with continued progress across all teams. Find out about our latest activities:
https://t.co/aJlvYy7MiM
Looking back on 2025, we are proud of a year marked by new projects, new team members, impactful publications, events, numerous reports produced, and extensive engagement across our community.
Here's our 2025 in numbers...
THANK YOU to everyone behind them ❤️⚙️
🚨NEW paper published in Alzheimer's & Dementia investigating the diagnostic accuracy and clinical utility of key Alzheiemer's disease-related plasma biomarkers.
Congratulations to all authors👏
@IHIEurope@goteborgsuni@IHI_PROMINENT
Check it out⤵️
https://t.co/SfE6NUcfjQ
Helmholtz Munich Launches Pioneering Osteoarthritis Research Project With EU Partners
👉https://t.co/JkdC3JjgB6
#HelmholtzMunich is part of #PROBE, a new EU-funded initiative aiming to transform how #osteoarthritis is diagnosed and treated. The project is supported by Horizon Europe through the Innovative Health Initiative and has a total budget of €26 million – €1.4 million of which is allocated to Helmholtz Munich.
🧬 Building the foundation for #PersonalizedMedicine
Osteoarthritis affects more than 500 million people worldwide. PROBE will integrate data from over 70 million individuals – enabling AI-driven analyses, predictive models, and innovative clinical study designs that pave the way for more precise diagnostics and tailored therapies.
🔍 Accelerating clinical impact
The consortium of 38 partners brings together expertise in #AI, data protection and ethics. The project aims to establish innovative endpoints, enhance therapy evaluation, and support shared decision-making for patients and clinicians.
💬 “With PROBE, we are uniting expertise and data across Europe to take osteoarthritis research to the next level. AI-powered analyses of federated multimodal data at unprecedented scale provide the foundation for personalized therapies and more efficient clinical trials – all with the clear goal of sustainably improving the quality of life for the hundreds of millions of people affected.”
– Prof. Eleftheria Zeggini, who leads Helmholtz Munich’s contribution to PROBE
@EleZeggini@fabian_theis@ja_schnabel@heinig_matthias@CompHealthMuc@HorizonEU@Novartis
#Osteoarthritis #AIinHealth #HorizonEU #OA #BigData
📢 We're excited to announce the official launch of
PROBE 👏
#PROBE is a pioneering initiative set to transform #osteoarthritis care through federated data and #AI-driven clinical innovation.
Learn more:
👉https://t.co/AL4OSSl3yM
According to official data from @CDTI_innovacion , SYNAPSE ranks among the Spanish organisations with the highest financial return from participation in Innovative Health Initiative (IHI) projects, alongside leading academic and healthcare institutions 👏
https://t.co/ctJViEFjet
🚨The SUSTAIN-HS Tool
An interactive platform for HTA stakeholders to track & share emerging methodological needs.
🗺️Map needs across Europe
🔍Contribute new methodological needs
📄Access reports
🔗Read more: https://t.co/1Dw3ZvTisQ
#SUSTAIN_HTA#HorizonEurope#HTA
Working in an HTA body? We want to hear from you!
The SUSTAIN-HTA consortium is conducting a survey on the methodological needs of HTA organisations.
Your input will help shape the future of HTA methods.
Take the survey here: https://t.co/OpqETPsVa9
#SUSTAIN_HTA#HorizonEurope
One year of #VICT3R in the books!
We’re excited to share a look back at the communication and dissemination highlights from the first 12 months of the project👏
More information:
👉 https://t.co/ulA25xbdp2
#Toxicology#AnimalWelfare#EthicalResearch#AI
💡Did you know that in 2021 about 57 million people were living with #dementia worldwide?
🧠Alzheimer's disease is the most common type of dementia and may contribute to 60–70% of cases.
📖https://t.co/lhkMbByFKO
#YourBrainMatters#BrainHealth#WAM2025#WorldAlzMonth
We're proud to share that we have contributed to three impactful scientific publications so far in 2025, underlining our commitment to advancing real-world data, AI, and data-driven research 🔬
Learn more here:
👉 https://t.co/RKTq4KOL0o
#RWD#AI#HealthResearch
“AI has to work in real life.” PROMINENT co-develops with people living with dementia & care partners, builds a digital decision-support platform for Alzheimer’s & sets up real-world evidence to monitor & evaluate new treatments in routine care. @0xbnd#WAM2025#WorldAlzhMonth